Sharps Technology Inc (NASDAQ: STSS) is a medical device and digital asset company that markets and distributes syringe products while holding Solana (SOL) cryptocurrency as its primary treasury reserve asset. Revenue is generated through product sales of disposable syringe inventory and staking rewards earned from SOL holdings. Following a settlement agreement executed on October 6, 2025, the company transferred its Hungarian subsidiary Safegard Medical Kft and certain patents to Plasto Technology Group LLC, exited its research and development activities, and reoriented as a medical device sales and distribution enterprise. As of December 31, 2025, the company held over 2.0 million SOL tokens, allocated under a Treasury Policy approved by its Board of Directors on December 20, 2025. Target customers for syringe products include foreign governments, hospitals, and healthcare groups. The company has no disclosed dominant market position among syringe distributors, and the filing names no direct competitors.

Revenue model

Product sales of disposable syringe inventory (transactional) and Solana staking rewards (SOL staked with validators on the proof-of-stake Solana network), per the FY2025 10-K filed 2026-03-31.

Products and services

Disposable syringe products (existing inventory held for distribution); Solana (SOL) digital asset holdings used for staking and treasury reserve; SOL-based call and put options disclosed as part of treasury strategy.

Customers and end markets

Prospective customers for syringe products include foreign governments, hospitals, and healthcare groups. The company is in ongoing discussions with healthcare companies and distributors as of the FY2025 filing. No customer concentration data disclosed.

Value-chain role

Downstream distributor and marketer of syringe products following exit from manufacturing and R&D. Also acts as a corporate SOL holder and staker, delegating to validators on the Solana proof-of-stake network to earn staking rewards.

Geographic exposure

U.S.-headquartered. Hungarian subsidiary Safegard Medical Kft was transferred to Plasto Technology Group LLC pursuant to the October 6, 2025 settlement agreement, exiting direct European operations.

Source: SEC 10-K, filed 2026-03-31

Industry: Surgical & Medical Instruments & Apparatus Peers: Arch Therapeutics, Inc. Nexgel Inc SURGALIGN HOLDINGS, INC. CHEMBIO DIAGNOSTICS, INC. Rapid Therapeutic Science Laboratories, Inc. Innovative Eyewear Inc Rockwell Medical Inc